Dagliflozin tablets belong to a new class of glucose-lowering drugs, mainly acting on the epithelial cells of kidney tubules, which can inhibit the absorption of glucose, and a large amount of sugar can be excreted from urine, thus playing a role in lowering sugar, which has good effect on the treatment of type 2 diabetes, but is not suitable for use in type 1 diabetes. In addition, Dagliflozin Tablets have another advantage in addition to its certain glucose-lowering effect. During the use of Dagliflozin Tablets, the patient’s heart failure can be relieved to a certain extent, which has a certain auxiliary effect on the protection of the heart. Patients with coronary heart disease combined with type 2 diabetes can prefer Dagliflozin Tablets. Dagliflozin Tablets can be used alone or in combination with other pro-secretory agents, including sulfonylurea pro-secretory agents, non-sulfonylurea pro-secretory agents, long-acting, short-acting and insulin sensitizing agents, glycosidase inhibitors, DPP-4 inhibitors and so on. It can also be used in combination with insulin, and the specific method of use should be guided by the doctor according to the patient’s specific situation. However, Dagliflozin Tablets also have certain side effects, such as easy to develop urinary tract infection, which is caused by the mechanism of action of Dagliflozin Tablets. After taking Dagliflozin Tablets, a large amount of sugar is excreted from the urine, and high sugar easily leads to the survival of various types of microorganisms, so urinary tract infection is easy to occur. In addition, there are some special cases in which Dagliflozin Tablets should not be used, such as patients with diabetic ketoacidosis and patients with hypotension, hypoglycemia and severe renal failure, so the specific use must be done under the doctor’s orders.